The Fiscal Year 2002 budget request for the NIA is $897,961,000, including AIDS, an increase of $93,509,000 and 11.9 percent over the FY 2001 level, and $191,992,000 and 27.9 percent over FY 2000.
A five year history of FTEs and Funding Levels for NIA are shown in the graphs below:
One of NIH's highest priorities is the funding of medical research through research project grants (RPGs). Support for RPGs allows NIH to sustain the scientific momentum of investigator-initiated research while providing new research opportunities. The Fiscal Year 2002 request provides an average cost increase for competing RPGs less than the Biomedical Research and Development Price Index (BRDPI) due to a one time adjustment for a major Alzheimer's Disease clinical trial funded in FY 2001. Noncompeting RPGs will receive increases of 3 percent on average for recurring direct costs.In FY 2002, total RPGs funded will be 1,344 awards, an increase of 69 awards over the FY 2001 estimate, the highest annual total ever awarded.
Promises for advancement in medical research are dependent on a continuing supply of new investigators with new ideas. In the Fiscal Year 2002 request, NIA will support 572 pre- and postdoctoral trainees in full-time training positions. An increase of 10 percent over Fiscal Year 2001 levels is provided for stipends and training-related expenses (e.g., health insurance, research supplies and equipment, and travel to scientific meetings).
The Fiscal Year 2002 request includes funding for 67 research centers, 205 other research grants, including 173 clinical career awards, and 65 R&D contracts. The R&D contracts mechanism also includes support for 13 contracts for the Extramural Clinical and Pediatric Loan Repayment Programs.
The NIA will invest additional Research Management and Support funds in the administration and oversight of its research programs and dissemination of health information to diverse populations. For example, NIA will dedicate significant program funds to search for new ways to prevent and treat Alzheimer's disease, with a special emphasis on testing interventions aimed at preventing the disease. Such efforts will require clinical trials on a scale never before attempted by the NIA, necessitating the creation of an oversight infrastructure of scientists who administer clinical trial programs and monitor data integrity. As special population groups grow at a faster rate than the population as a whole, unprecedented opportunities exist not only to increase the participation of diverse populations in research programs, but also to develop strategies to disseminate information for improving health behaviors. Outreach programs will also target enhanced education efforts for health professionals to increase their understanding of an aging population.
The mechanism distribution by dollars and percent change are displayed below: